New Production Site BASF Relocates Production of Pharmaceutical Excipient to its Minden Site
BASF will transfer the production of the pharmaceutical excipient Kolliphor TPGS from Kankakee, Illinois, to its German facility Minden. The production is expected to start in the first quarter of 2013. The goal is to reduce the complexity of both manufacturing sites.
Ludwigshafen – The pharmaceutical excipient Kolliphor TPGS of BASF, which can enhance the bioavailability of poorly soluble active substances, will be manufactured in Germany in the future: “Expanding the Kolliphor TPGS manufacturing capacity at our Minden site is another example of BASF’s commitment to the pharmaceutical and dietary supplement market. The relocation creates a more centralized production facility, reduces complexity in the production setup, and provides room for future expansion,” says Dr. Thorsten Schmeller, Head of Global Marketing New Products at BASF’s Global Business Unit Pharma Ingredients & Services.
Until the production in Minden is fully operational, BASF will continue to manufacture the excipient at the Kankakee site. The production start in Germany is planned for spring 2013. “We have scheduled a generous supply overlap that we expect allows for a seamless transition,” adds Schmeller. “Our projection also takes into account the appropriate qualification period required to transition products used in pharmaceutical applications.”
Kolliphor TPGS is a water-soluble derivative of vitamin E. It is commonly used in pharmaceutical and nutritional formulations, but also in cosmetics. Additionally it has plasticizing effects that are beneficial for emerging platform technologies in the pharmaceutical industry such as hot melt extrusion.
Kankakee will continue to be an important production site for the company. Besides food ingredients, the company manufactures ingredients for soaps, shampoos, detergents, coatings, inks and adhesives at the site.